Our virtual HEPATOPAC®️ User Group Meeting (HUGM) is an annual symposium at which researchers share information about innovative methods and study designs using long-term HEPATOPAC and HEPATOMUNE cultures. Featuring Dr. Umehera, Roche, Dr. Clasquin, Pfizer, and Dr. Cottier, BioIVT, the 2022 HUGM agenda includes presentations on assessing DDI risk assessment for low clearance compounds, knockdown of a hepatically expressed protein with a long half-life, and novel methods to investigate NAFLD. Can We Buy You Lunch? Let us know if you would like to receive a $20, €20 or £20 UberEats voucher, which will be sent 24 hours before the meeting starts.
Speakers
Kenichi Umehera PhD
Senior Principal Scientist, Roche Pharmaceutical Research and Early Development
Michelle Clasquin, PhD
Research Fellow and Lab Head in Internal Medicine Research Unit, Pfizer
Karissa Cottier, PhD
Principal Scientist, BioIVT
Agenda
10:00
-
10:05
Opening Remarks
10:05
-
11:00
The Use of HEPATOPAC for Estimation of Fraction Metabolized by Cytochrome P450 (CYP) Enzymes
Speaker: Kenichi Umehera PhD, Senior Principal Scientist, Roche Pharmaceutical Research and Early Development
11:00
-
12:00
Generating a Primary Human Hepatocyte Isogenic Pair Using BioIVT’s HEPATOPAC
Speaker: Michelle Clasquin, PhD, Research Fellow and Lab Head in Internal Medicine Research Unit, Pfizer
12:00
-
01:00
Mimicking Fatty Liver Disease in HEPATOPAC: Examining Changes in Gene Expression and Outcomes of Gene Knockdown
Speaker: Karissa Cottier, PhD, Principal Scientist, BioIVT
